Browse

A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer

Cited 28 time in Web of Science Cited 30 time in Scopus
Authors
Oh, Do-Youn; Cha, Yongjun; Choi, In-Sil; Yoon, So-Young; Kim, Jee Hyun; Kim, Chang Duck; Bang, Yung-Jue; Kim, Yeul Hong; Kim, Jae Sun; Oh, Sang Cheul; Choi, In Keun
Issue Date
2010-02
Publisher
SPRINGER
Citation
CANCER CHEMOTHERAPY AND PHARMACOLOGY; Vol.65 3; 527-536
Keywords
GemcitabineS-1PalliativePancreatic cancer
Abstract
To confirm the efficacy and toxicity of gemcitabine and S-1 combination chemotherapy when used as a first-line therapy in patients with unresectable pancreatic cancer. Patients with locally advanced or metastatic or recurrent pancreatic adenocarcinoma, which was histologically or cytologically proven, with at least one measurable lesion were eligible for the study. Gemcitabine at a dose of 1,000 mg/m(2) was intravenously given over 30 min on days 1 and 8, while S-1 at a dose of 40 mg/m(2) was orally given twice daily from day 1 to 14, and the cycle was repeated every 3 weeks. The objective response rate, which was assessed according to RECIST criteria, was the primary end point. A total of 38 patients were enrolled between June 2006 and June 2007. The median number of treatment courses was 5.5 (range 1-22). Thirty-four patients were evaluable for response. Although no complete response was seen, partial responses were achieved in 11 patients, resulting in an overall response rate of 32% [95% confidence interval (CI) 17-48%]. The median response duration was 6.0 months (95% CI 4.6-8.3 months), the median time-to-progression was 5.4 months (95% CI 2.9-8.0 months), and the median overall survival was 8.4 months (95% CI 5.7-11.1 months). The major grade 3/4 hematologic toxicities were neutropenia (39.5%), leukopenia (15.8%), thrombocytopenia (2.6%), and anemia (7.9%). The major grade 3/4 non-hematologic toxicities included anorexia (10.5%), stomatitis (2.6%), rash (7.9%), fatigue (7.9%) and hyperbilirubinemia (5.3%). Gemcitabine and S-1 combination chemotherapy was effective and tolerable in patients with unresectable pancreatic cancer.
ISSN
0344-5704
Language
English
URI
http://hdl.handle.net/10371/76577
DOI
https://doi.org/10.1007/s00280-009-1059-9
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse